Compassionate Use of Ibalizumab for the Treatment of HIV Infection

NO_LONGER_AVAILABLE

Conditions studied: Human Immunodeficiency Virus (HIV)

In brief

Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+ lymphocytes. Ibalizumab has completed phase I and II clinical studies in HIV-negative and HIV-infected individuals showing safety and efficacy for suppressing HIV replication.

Key facts

Study ID

NCT02028819

Run by

University of Colorado, Denver

Starts

2012-01-01

Expected to finish

2014-02-01

Last updated by the study team

2016-11-01

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with a diagnosis of HIV-infection with resistance or intolerance to currently available antiretroviral medications available in the United States or in whom additional drugs need to be added to their regimen because of inadequate response to existing therapy
• Patients with HIV infection that is expected to be sensitive to dolutegravir and ibalizumab
• Patients who do not qualify for or who are otherwise ineligible for clinical trials of medications not currently approved for treatment of HIV infection in the U.S.

You may not qualify if…

• Patients who are allergic to or have had a severe adverse reaction to dolutegravir or ibalizumab in the past.
• Age <18 years or >89 years
• Women may not be pregnant
• Prisoners and decisionally challenged patients will be excluded

Where it is running

• Denver Health — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.